JP Morgan Chase’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-274,282
| Closed | -$1.6M | – | 7480 |
|
|
2022
Q4 | $1.6M | Buy |
274,282
+186,915
| +214% | +$983K | ﹤0.01% | 3730 |
|
|
2022
Q3 | $585K | Buy |
87,367
+41,018
| +88% | +$249K | ﹤0.01% | 4357 |
|
|
2022
Q2 | $195K | Buy |
46,349
+46,307
| +110,255% | +$183K | ﹤0.01% | 5097 |
|
|
2022
Q1 | $0 | Hold |
42
| – | – | ﹤0.01% | 7203 |
|
|
2021
Q4 | $0 | Sell |
42
-2,262
| -98% | -$7.53K | ﹤0.01% | 7142 |
|
|
2021
Q3 | $8K | Sell |
2,304
-34,880
| -94% | -$122K | ﹤0.01% | 6206 |
|
|
2021
Q2 | $157K | Sell |
37,184
-120,586
| -76% | -$510K | ﹤0.01% | 5358 |
|
|
2021
Q1 | $787K | Buy |
157,770
+752
| +0.5% | +$6.08K | ﹤0.01% | 4400 |
|
|
2020
Q4 | $1.99M | Buy |
157,018
+48,875
| +45% | +$557K | ﹤0.01% | 3480 |
|
|
2020
Q3 | $1.04M | Sell |
108,143
-6,939
| -6% | -$68.4K | ﹤0.01% | 3621 |
|
|
2020
Q2 | $1.15M | Sell |
115,082
-16,635
| -13% | -$160K | ﹤0.01% | 3431 |
|
|
2020
Q1 | $1.16M | Sell |
131,717
-36,237
| -22% | -$357K | ﹤0.01% | 3313 |
|
|
2019
Q4 | $1.55M | Buy |
167,954
+12,317
| +8% | +$87.3K | ﹤0.01% | 3567 |
|
|
2019
Q3 | $915K | Buy |
155,637
+5,045
| +3% | +$53.5K | ﹤0.01% | 3886 |
|
|
2019
Q2 | $1.77M | Buy |
150,592
+2,097
| +1% | +$22.6K | ﹤0.01% | 3473 |
|
|
2019
Q1 | $1.79M | Sell |
148,495
-643
| -0.4% | -$9.48K | ﹤0.01% | 3408 |
|
|
2018
Q4 | $1.87M | Sell |
149,138
-37,693
| -20% | -$520K | ﹤0.01% | 3324 |
|
|
2018
Q3 | $2.77M | Buy |
186,831
+34,920
| +23% | +$549K | ﹤0.01% | 3227 |
|
|
2018
Q2 | $2.56M | Buy |
151,911
+5,403
| +4% | +$105K | ﹤0.01% | 3219 |
|
|
2018
Q1 | $3.35M | Sell |
146,508
-11,558
| -7% | -$257K | ﹤0.01% | 2901 |
|
|
2017
Q4 | $4.09M | Buy |
+158,066
| New | +$3.18M | ﹤0.01% | 2842 |
|
|
2017
Q3 | – | Sell |
-3,099
| Closed | -$43K | – | 5263 |
|
|
2017
Q2 | $43K | Sell |
3,099
-49,684
| -94% | -$732K | ﹤0.01% | 4379 |
|
|
2017
Q1 | $900K | Buy |
52,783
+11,392
| +28% | +$137K | ﹤0.01% | 3454 |
|
|
2016
Q4 | $426K | Buy |
41,391
+31,321
| +311% | +$286K | ﹤0.01% | 3853 |
|
|
2016
Q3 | $102K | Buy |
+10,070
| New | +$110K | ﹤0.01% | 3861 |
|
|
2016
Q1 | – | Sell |
-35
| Closed | -$1K | – | 5020 |
|
|
2015
Q4 | $1K | Sell |
35
-30,000
| -100% | -$652K | ﹤0.01% | 4631 |
|
|
2015
Q3 | $564K | Buy |
+30,035
| New | +$510K | ﹤0.01% | 3367 |
|
|
2014
Q2 | – | Sell |
-227,250
| Closed | -$3.06M | – | 3651 |
|
|
2014
Q1 | $3.06M | Buy |
+227,250
| New | +$3.21M | ﹤0.01% | 2356 |
|
JP Morgan Chase's CNCE Position: Q1 2023 in Review
JP Morgan Chase sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 274,282 shares — an estimated $1.6M sold.
JP Morgan Chase first reported a position in CNCE in Q1 2014 and held it in 28 quarters. The position peaked at $4.09M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- JP Morgan Chase reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- JP Morgan Chase sold 274,282 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.6M.
- JP Morgan Chase first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 28 quarters.
- JP Morgan Chase's Concert Pharmaceuticals, Inc. position peaked at $4.09M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.